Open AccessB-cell–specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion
Author(s) -
Daniela Asslaber,
Yuan Qi,
Nicole Maeding,
M. Steiner,
Ursula Denk,
Jan Philip Höpner,
Tanja Nicole Hartmann,
Nadja Zaborsky,
Richard Greil,
Alexander Egle
Publication year - 2019
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood.2019000973
Subject(s) - downregulation and upregulation , irf4 , immune system , chronic lymphocytic leukemia , immunology , cancer research , evasion (ethics) , antigen , biology , leukemia , gene , transcription factor , genetics
Key Points IRF4 deletion in Tcl-1 tg mice and IRF4low CLL patients enhances disease progression due to increased tumor immune evasion. This is caused by a downregulation of the antigen processing and presentation machinery and reduced T-cell costimulation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom